GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

GeneDx Holdings Corp. Class A Common Stock

GeneDx is focused on delivering personalized, actionable insights that improve health outcomes. We sit at the intersection of diagnostics and data science, pairing decades of genomic expertise with an unmatched ability to interpret clinical data at scale.

Our exome and genome testing is among the best in the industry. We expect that it will be even more advanced in the future with the help of Centrellis®, our innovative health information platform. Powered by millions of medical records, Centrellis® integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data.

As a result of our robust test menu, including our exome and genome testing, and the comprehensive insights generated by Centrellis®, we are developing a more complete understanding of complex disease than ever before. This translates to faster diagnosis, more effective treatment plans, and enhanced drug discovery.

Our offerings help a whole spectrum of healthcare partners -- clinicians, researchers, health systems, pharmaceutical companies, and payors -- improve patient experiences and advance population health.

GeneDx

Congratulations to Akouos on the news of their investigational #gene therapy treatment for otoferlin gene (OTOF)-mediated hearing loss, a rare congenital deafness impacting roughly 200,000 people worldwide. GeneDx is proud to partner with Akouos to help accelerate enrollment in #clinicaltrials by leveraging our robust dataset to identify other #patients who can benefit from these #therapies. We’re humbled to be part of the ecosystem of #healthcare innovation and improving access to pioneering treatments for more patients. 

https://nyti.ms/3OlRYAK

9 state #Medicaid programs now cover rapid whole #genome #sequencing (rWGS) in the #pediatric inpatient setting.  

Utah joins a growing list of states who recognize the importance of offering rWGS in the #NICU and PICU to provide a rapid #diagnosis for the most vulnerable patients and their families.

Couldn’t be prouder of the entire team at GeneDx on an outstanding fourth quarter. Our preliminary results put us ahead on revenue and cash burn goals. We’re proving that we can work together as a team committed to our patients, our providers, our partners, and to our shareholders. 2024 is already off to a strong start. Thank you to everyone for helping keep our eyes on the goal of diagnosing inherited disease earlier, connecting people with the right treatment, and driving a healthier future for as many families as possible.
https://lnkd.in/eHQUhcK8

Harness deep #genomic data. Provide more definitive #answers. Deliver improved outcomes. With one of the world’s largest #raredisease clinical data sets, GeneDx can help you bring #precision medicine into your practice. Our vision is big: leverage tomorrow’s technology to improve patients’ lives, today.

Uncertainty and delayed diagnoses are too common among patients with #neurodevelopmental disorders (NDDs). That’s why leading medical societies recognize #exome or #genome #sequencing as the best, first-tier #genetic testing option. 

For a child with NDDs, every day without a genetic #diagnosis is a missed opportunity. With GeneDx exome testing, you can provide more timely, cost-effective, and comprehensive clinical evaluations that deliver actionable insights. 

Choose a comprehensive and cost-effective genetic testing option supported by leading medical societies.

There’s no place like home for the #holidays. But for the most vulnerable #patients and their families, this isn’t always a possibility. Give them the gift of #genetic insights that can help inform #diagnosis, direct #treatment, and make sure they’re back where they belong: in the arms of their loved ones.

Five. That’s how many uninformative tests the average child with #neurodevelopmental disorders undergoes in search of a #genetic diagnosis. Find critical information sooner by ordering GeneDx #exome first. Test once, discover more, and help your #patients get the care they need #earlier.

Incorporating comprehensive #genomic #sequencing into your workflow doesn’t have to be complicated. Instead, let us do the heavy lifting. We can assist with: 
✅ selecting appropriate tests 
✅ answering #clinical questions 
✅ reporting patient-centric #results 
✅ guiding potential next steps 
 
With comprehensive care from start to finish, GeneDx offers more than a test result: we deliver actionable insights that promote optimal #health.

Are you a #healthcare provider working in a #NICU? Do you want to implement rapid #GeneticTesting, but lack genetic specialist support?

Learn how to interpret #genetic results & discuss them with caregivers, with insights from a panel of experts. 

Click here, watch at your convenience & earn 1 #CME credit 👉 https://bit.ly/47lLd9N

What more can you do for your patients in the #NICU? Rapid whole #genome sequencing (rWGS) might be the answer. It’s been shown to: 
✅ Change clinical management in 61% of patients 
✅ Reduce the length of NICU stays by >457 days 
✅ Reduce #healthcare costs by $12K-16K per #patient 
 
Learn more about the power of #rWGS by visiting the GeneDx team at the Nemours Children's #Neonatology Conference in Oxon Hill, MD. We look forward to seeing you!

	Dec '20	Dec '21	Dec '22	Dec '23
account payables	26.74M -	44.69M 67.16%	46.02M 2.96%	10.24M 77.75%
accumulated other comprehensive income loss				425K -
cash and cash equivalents	108.13M -	400.57M 270.44%	123.93M 69.06%	99.68M 19.57%
cash and short term investments	108.13M -	400.57M 270.44%	123.93M 69.06%	130.15M 5.01%
common stock		24K -	38K 58.33%	2K 94.74%
deferred revenue	1.78M -	473K 73.47%	40K 91.54%
deferred revenue non current				62.94M -
deferrred tax liabilities non current			2.66M -	56.48M 2,024.03%
goodwill
goodwill and intangible assets			186.65M -	172.63M 7.51%
intangible assets			186.65M -	172.63M 7.51%
inventory	24.96M -	33.46M 34.03%	13.66M 59.16%	8.78M 35.77%
long term debt	39.75M -	29.43M 25.97%	66.26M 125.18%	52.69M 20.49%
long term investments				987K -
net debt	-63.11M -	-367.72M 482.70%	-51.55M 85.98%	20.09M 138.97%
net receivables	32.33M -	26.56M 17.85%	43.34M 63.17%	32.82M 24.29%
other assets
other current assets	4.12M -	3.80M 7.81%	6.39M 68.07%	10.60M 65.85%
other current liabilities	39.65M -	52.70M 32.92%	92.12M 74.80%	44.44M 51.76%
other liabilities
other non current assets	14.42M -	7.83M 45.72%	7.38M 5.68%	3.43M 53.61%
other non current liabilities	468.50M -	35.28M 92.47%	24.02M 31.92%	14.74M 38.65%
othertotal stockholders equity		963.52M -	1.38B 43.03%	1.53B 10.86%
preferred stock
property plant equipment net	63.11M -	62.72M 0.62%	84.28M 34.39%	59.38M 29.55%
retained earnings	-330.05M -	-575.44M 74.35%	-1.12B 95.40%	-1.30B 15.63%
short term debt	5.28M -	3.42M 35.20%	6.12M 79.03%	4.14M 32.30%
short term investments				30.47M -
tax assets				54.92M -
tax payables
total assets	251.64M -	554.09M 120.19%	490.94M 11.40%	473.67M 3.52%
total current assets	174.11M -	483.54M 177.73%	212.62M 56.03%	182.34M 14.24%
total current liabilities	73.44M -	101.28M 37.91%	144.30M 42.47%	58.82M 59.24%
total debt	45.02M -	32.85M 27.05%	72.38M 120.37%	119.77M 65.46%
total investments				31.45M -
total liabilities	581.69M -	165.99M 71.46%	237.24M 42.92%	245.66M 3.55%
total liabilities and stockholders equity	251.64M -	554.09M 120.19%	490.94M 11.40%	473.67M 3.52%
total non current assets	77.53M -	70.55M 9.01%	278.32M 294.51%	291.33M 4.68%
total non current liabilities	508.25M -	64.71M 87.27%	92.94M 43.63%	186.84M 101.03%
total stockholders equity	-330.05M -	388.10M 217.59%	253.71M 34.63%	228.02M 10.13%

COM:GENEDX

GeneDx Holdings Corp.

Last Close

72.07

22/11 21:00

Market Cap

2.16B

Beta: -

Volume Today

549.30K

Avg: -

Preview